BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Methotrexate
Drug: Abatacept placebo
Drug: Methotrexate placebo

First Posted Date: 2010-06-11

Last Posted Date: 2016-01-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 511

Registration Number: NCT01142726

Locations: 🇺🇸
Johns Hopkins University Division Of Rheumatology, Baltimore, Maryland, United States
🇺🇸
Physician Research Collaboration, Llc, Lincoln, Nebraska, United States
🇺🇸
Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States

and more 13 locations

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Phase 2

Withdrawn

Conditions: Chronic Hepatitis C Virus Genotype 1

Interventions: Drug: BMS-824393
Drug: Placebo
Drug: Peginterferon Alpha-2a
Drug: Ribavirin

First Posted Date: 2010-06-11

Last Posted Date: 2011-03-15

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01142700

Locations: 🇺🇸
Local Institution, Philadelphia, Pennsylvania, United States
🇺🇸
Research And Education, Inc., San Diego, California, United States
🇺🇸
Gastrointestinal Specialists Of Georgia Pc, Mareitta, Georgia, United States

and more 7 locations

Dose Escalation With Remicade® and Orencia®

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-06-10

Last Posted Date: 2012-04-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5451

Registration Number: NCT01141413

Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-06-07

Last Posted Date: 2011-05-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1810

Registration Number: NCT01137838

Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-06-07

Last Posted Date: 2010-10-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3940

Registration Number: NCT01137851

Pediatric Catheter-related Thrombosis Imaging Study

Not Applicable

Completed

Conditions: Thrombosis

Interventions: Procedure: Ultrasound
Drug: Magnetic Resonance Imaging with Contrast
Procedure: Magnetic Resonance Imaging without Contrast

First Posted Date: 2010-06-04

Last Posted Date: 2014-12-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 151

Registration Number: NCT01137578

Locations: 🇺🇸
Children'S Hopsital Of Pittsburgh Of Upmc, Pittsburgh, Pennsylvania, United States
🇺🇸
Arkansas Children'S Hospital, Little Rock, Arkansas, United States
🇺🇸
The Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

and more 8 locations

Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-06-03

Last Posted Date: 2012-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 695

Registration Number: NCT01136694

Predictors of Adherence to Orencia

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-06-03

Last Posted Date: 2016-09-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 422

Registration Number: NCT01136707

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Placebo
Drug: Daclatasvir
Drug: peg-interferon alfa-2a
Drug: ribavirin

First Posted Date: 2010-05-18

Last Posted Date: 2015-10-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 558

Registration Number: NCT01125189

Locations: 🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸
Cli, Los Angeles, California, United States

and more 33 locations

Safety and Pharmacology Study of BMS-866949

Phase 1

Terminated

Conditions: Major Depression

Interventions: Drug: Placebo
Drug: BMS-866949

First Posted Date: 2010-05-17

Last Posted Date: 2012-03-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 47

Registration Number: NCT01124344

Locations: 🇸🇪
Local Institution, Uppsala, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy